Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma

ABSTRACT High-risk neuroblastoma is an aggressive childhood cancer with poor outcomes. Treatment begins with an induction phase comprised of intense multi-agent chemotherapy with the goal of maximally reducing tumor bulk. Given the high intensity of induction chemotherapy, neutropenic fever and infectious complications are common; however, the actual incidence is difficult to determine from clinical trial reports. We performed a retrospective review of infection-related complications in 76 children treated for high-risk neuroblastoma at Texas Children's Hospital. Medical records were reviewed for demographics, febrile neutropenia (FN) episodes, presence, and type of bacterial and fungal infections, and potential risk factors for infection. Fifty-seven percent of patients developed one or more serious bacterial or fungal infections during induction chemotherapy. Additionally, over 75% of patients had at least one admission for FN. Risk factors for developing any infection included female sex, MYCN amplification, and having Medicaid. Patients with external central venous catheters and those requiring parenteral nutrition had higher rates of bacteremia or fungemia. Each cycle, 50% were readmitted for either FN or infection. The overall burden of infectious complications was high, with 70% having two or more unplanned admissions for infection or FN. The incidence of febrile neutropenia and serious bacterial and fungal infections during induction chemotherapy for high-risk neuroblastoma is high. Most patients had at least two additional hospitalizations for infectious complications. Risk factors including female sex, MYCN amplification, payer status, and type of central access were associated with higher rates of infection in this cohort. Abbreviations: CLABSI Central line associated blood stream infection; CTCAE Common Terminology Criteria for Adverse Events; FN Febrile neutropenia; ANC Absolute neutrophil count; TPN Total parenteral nutrition.

[1]  J. Gralla,et al.  Risk factors for bacteremia and central line–associated blood stream infections in children with acute myelogenous leukemia: A single‐institution report , 2017, Pediatric blood & cancer.

[2]  A. Troxel,et al.  Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  V. Hendricks-Ferguson,et al.  Understanding Effective Delivery of Patient and Family Education in Pediatric Oncology: A Systematic Review From the Children’s Oncology Group , 2016, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

[4]  L. Dynan,et al.  Attributable Cost and Length of Stay for Central Line–Associated Bloodstream Infections , 2014, Pediatrics.

[5]  A. Colevas,et al.  Adverse event monitoring in oncology clinical trials , 2013 .

[6]  P. Vanhems,et al.  Propensity score analysis confirms the independent effect of parenteral nutrition on the risk of central venous catheter-related bloodstream infection in oncological patients. , 2013, Clinical nutrition.

[7]  J. Traubici,et al.  Incidence, Risk Factors, and Outcomes of Enteritis, Typhlitis, and Colitis in Children With Acute Leukemia , 2013, Journal of pediatric hematology/oncology.

[8]  John M Maris,et al.  Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. , 2013, The Lancet. Oncology.

[9]  F. Gibson,et al.  Guideline for the management of fever and neutropenia in children with cancer and/or undergoing hematopoietic stem-cell transplantation. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Martin Krapcho,et al.  SEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations) , 2012 .

[11]  A. Cruz,et al.  Implementation of Goal-Directed Therapy for Children With Suspected Sepsis in the Emergency Department , 2011, Pediatrics.

[12]  D. Machin,et al.  Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Robin E. Matutina Educating families of children newly diagnosed with cancer: Parents require information in an easy-to-read format to enable them to care for their children. Robin Matutina describes an initiative to simplify education materials , 2010 .

[14]  W. Woods,et al.  Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia , 2009, Cancer.

[15]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Zaoutis,et al.  Infections in pediatric acute myeloid leukemia: Lessons learned and unresolved questions , 2008, Pediatric blood & cancer.

[17]  D. Machin,et al.  High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. , 2008, The Lancet. Oncology.

[18]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[19]  K K Matthay,et al.  Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic Acid , 1999 .

[20]  S. Mårild,et al.  Incidence rate of first‐time symptomatic urinary tract infection in children under 6 years of age , 1998, Acta paediatrica.

[21]  A. Hellström,et al.  Association between urinary symptoms at 7 years old and previous urinary tract infection. , 1991, Archives of disease in childhood.